How Pressure Swing Adsorption produces hospital-grade oxygen on site, why hospitals worldwide are switching from cylinders, and how to choose the right system for your facility. Engineered in Lisbon since 1981, deployed in 80+ countries.
For decades, hospitals depended on external oxygen supply chains: cylinders delivered by truck, liquid oxygen tanks refilled on schedule, and the constant anxiety of running out. Today, hospitals, ministries of health, and healthcare organisations worldwide are making a different choice. They produce their own medical oxygen on site, at the point of care, continuously and reliably, using Pressure Swing Adsorption technology.
PSA stands for Pressure Swing Adsorption. It is a proven industrial and medical process that separates oxygen from the surrounding air. Unlike oxygen produced in a factory, bottled, and transported, a PSA system generates oxygen continuously from the air available at your location.
The entire process operates automatically, around the clock, without requiring the presence of an operator. Modern systems like the ULTRAOX include continuous gas monitoring, automated failover to a backup oxygen source if parameters drift outside specification, and remote diagnostics for real-time oversight. ULTRAOX was the first PSA oxygen production plant to be certified as a medical device under the European Directive.
Once installed, a PSA generator gives a hospital permanent supply chain independence. As long as the facility has electricity and air, it has oxygen.
The PSA process operates in continuous cycles measured in seconds. Two zeolite columns alternate between adsorption and regeneration so the supply to the hospital pipeline never stops.
Filtered ambient air containing 21% oxygen, 78% nitrogen, and trace gases is drawn in and compressed by an oil-free compressor. The air is dried to remove moisture, oil vapour, and particulates. Oil-free compression is non-negotiable for medical oxygen.
Oil-free compressionCompressed air enters one of two columns filled with zeolite molecular sieve, a porous material that selectively adsorbs nitrogen molecules under pressure. Oxygen passes through to the buffer tank, reaching purity of up to 95%, exceeding pharmacopoeia minimums.
95% purity outputWhile one column produces oxygen, the other depressurises and vents nitrogen to atmosphere. The cycle alternates every few seconds, providing uninterrupted Oxygen 93 grade output to the EN ISO 7396-1 hospital pipeline. Output never stops, even during regeneration.
EN ISO 7396-1 readyOnboard sensors continuously track O₂ purity plus residual CO, CO₂, and water vapour levels. If any parameter drifts outside specification, the system automatically alarms and switches to the cylinder backup source. Zero operator intervention required for normal operation.
Auto-failover · zero operatorThe shift toward on-site PSA oxygen generation is not a trend. It is a structural change in how healthcare systems think about critical medical infrastructure.
Every hospital relying on delivered oxygen is exposed to the same risks: supplier delays, transport disruptions, fuel volatility, and road infrastructure failures. During the COVID-19 pandemic, hospitals in dozens of countries ran out of oxygen. The cause was not lack of oxygen in the atmosphere. It was inability of supply chains to scale fast enough. Facilities with PSA generators kept operating.
Cylinder and liquid oxygen carry high recurring costs: the gas itself, delivery charges, cylinder rental fees, handling, and labour. A PSA generator replaces almost all recurring costs with a single input: electricity. Capital investment is typically recovered within 12 to 36 months. Over a 10-year operational lifespan, savings often exceed 70 percent of equivalent cylinder supply cost.
A well-designed PSA system operates 24 hours a day, 7 days a week, 365 days a year. Oxygen is produced on demand, matched to actual consumption. There is no risk of running low at the end of a delivery cycle, no weekend shortfalls, no emergency orders. Duplexed systems with two parallel production lines provide additional redundancy if one line requires maintenance.
The World Health Organisation recognises on-site PSA oxygen generation as appropriate for medical oxygen production in healthcare facilities. Certified systems holding ISO 13485, CE 1639, and MDR Class IIb satisfy requirements of most international procurement processes, including UN agency tenders and bilateral health programmes. ULTRAOX was the first PSA plant certified as a medical device under European Directive.
No single oxygen supply method is right for every facility. The correct choice depends on hospital size, supply chain reliability, electricity availability, and oxygen consumption volume.
12–36 mo95% Oxygen 9310–15 Nm³/h demand
ULTRAOX was the first PSA oxygen production plant certified as a medical device under the European Directive. Engineered and manufactured in Lisbon since 1981, deployed in hospitals, ministries of health, UN agencies, and NGO programmes across more than 80 countries.
The containerised ULTRAOX CO system is engineered for deployment in extreme operating conditions: high-altitude clinics, desert hospitals, tropical humidity, and below-freezing latitudes. Pre-assembled, factory-tested, and ready in 24 to 72 hours.
Every ULTRAOX is assembled in our Lisbon facility under ISO 13485:2016 quality control. Oil-free compressors, premium zeolite molecular sieves, redundant gas analysers, and continuous monitoring systems all integrated into a single CE 1639 certified medical device.
Real PSA oxygen plants delivered, commissioned, and supported by Ultra Controlo. Ministries of health, UN agencies, the Global Fund, and NGO partners across Africa, the Middle East, and Latin America.
A ULTRAOX ST PSA generator with redundant compression and dual-tower production serves a 220-bed regional referral hospital across the Sotavento islands. Twin-tower configuration ensures continuous supply during maintenance windows.
A ULTRAOX duplex PSA system at Hôpital Dermatologie de Bamako and a Ministerial inauguration of an ULTRAOX in Kayes by Colonel Major Dr Assa Badiallo Touré. National oxygen production capacity strengthened across two regions.
A high-capacity ULTRAOX 180D ST with 2×ULTRASCREW 37 VSD PM oil-free compressors and 2×ULTRACON 10 PSA modules. Designed for high-demand regional hospital operations under challenging supply conditions.
Inauguration of ULTRAOX at Hospital de Benguela under a national UNDP and Global Fund programme covering up to 8 hospitals nationwide. Complete supply, installation, training, and lifecycle support across regional facilities.
An ULTRAOX system operating at high altitude in the Peruvian Andes, supplying critical care services to remote mountain populations. Demonstrates ULTRAOX viability across extreme operating environments and altitudes.
Companion ULTRAAR ME 2.60/1000 UD DS 4G PO medical air plant with 2×ULTRASCREW 7 FSD compressors, 1000L receiver, and full ULTRADRY treatment chain. Demonstrates Ultra Controlo's complete medical gas pipeline capability.
Choosing the right PSA system requires understanding your facility's actual and projected oxygen demand. Five factors determine the appropriate system size.
Ultra Controlo's engineering team provides free pre-project site assessments and system sizing consultations as part of every project enquiry.
Request free sizing assessmentMedical oxygen systems must be sized for peak demand, not average demand. Peak typically occurs in the ICU, operating theatres, and emergency departments simultaneously. A system sized only for average consumption will be insufficient during high-demand events.
General ward beds typically consume less oxygen per hour than ICU or surgical beds. A hospital with 10 ICU beds may consume more oxygen than one with 50 general ward beds. Specialty mix affects total demand significantly.
Hospital pipeline systems typically operate at 4 bar. The PSA system must maintain this pressure at peak flow continuously. ULTRAOX outlet pressure spans 4 to 10 bar across all configurations to suit varied pipeline standards.
Regulatory requirements and clinical risk assessments often mandate a backup oxygen source: either a cylinder manifold or a second PSA production line, to cover maintenance periods and system faults. Duplex configurations provide built-in redundancy.
A system sized only for current demand may be insufficient within 3 to 5 years. Modular systems, where additional production capacity can be added as demand grows, are preferable for facilities undergoing expansion. ULTRAOX modular design supports incremental capacity growth.
A hospital PSA oxygen generator must satisfy multiple international standards. ULTRAOX holds the complete medical-device compliance stack.
Medical device certification under the European Medical Device Regulation. Required for hospital oxygen generators sold or operated in the EU and aligned markets.
Quality management system certification for medical device manufacturers. Governs design, production, and post-market surveillance processes throughout the device lifecycle.
European standard for medical gas pipeline systems. Specifies design, installation, function, performance, documentation, testing, and commissioning of compressed medical gas pipelines.
Pharmacopoeia grade designation for medical oxygen produced by PSA. Both European Pharmacopoeia and US Pharmacopeia specify minimum 93% purity (±3%) for clinical use.
Answers from our engineering team to the questions hospital procurement, biomedical engineers, and ministries of health most often ask.
A PSA (Pressure Swing Adsorption) medical oxygen generator is a medical device that produces oxygen continuously from ambient air at the point of care. It separates oxygen from nitrogen using zeolite molecular sieves under alternating pressure cycles, delivering up to 95% pure oxygen directly to the hospital pipeline.
ULTRAOX was the first PSA oxygen plant certified as a medical device under the European Directive.
Yes. PSA-generated oxygen meeting pharmacopoeia purity standards (Oxygen 93, minimum 93% O₂) is clinically equivalent to cylinder or liquid oxygen and is appropriate for all hospital applications, including:
Mechanical ventilation, anaesthesia, neonatal care, hyperbaric oxygen therapy, surgical theatres, ICU bedside delivery, and emergency resuscitation.
Installation timelines vary by facility:
Indoor installation (ULTRAOX SC or ST) in a prepared technical room can be commissioned within 2 to 4 weeks of equipment arrival.
Containerised installation (ULTRAOX CO) can be operational in 24 to 72 hours, as systems arrive pre-assembled and require only utility connections.
Power consumption depends on production capacity. As a general reference, a system producing 20 Nm³/hour of oxygen typically consumes approximately 7 to 10 kW.
Ultra Controlo provides precise power specifications during the site assessment phase and offers UltraGreen renewable-energy compatibility for solar-powered or hybrid installations.
A well-designed PSA system requires periodic preventive maintenance every 6 to 12 months. This covers filter replacement, zeolite sieve inspection, compressor servicing, and calibration of the monitoring system.
Ultra Controlo's UltraCare programme provides scheduled preventive maintenance, corrective maintenance on demand, 24/7 international technical support, and a genuine spare parts service.
Yes. The World Health Organisation recommends on-site PSA oxygen generation as an appropriate method for producing medical oxygen in healthcare facilities, particularly in low- and middle-income countries.
WHO technical specifications for PSA oxygen generators are publicly available and consistent with the design parameters of certified systems like ULTRAOX.
A hospital PSA oxygen generator must hold:
CE marking under MDR (EU) 2017/745 as a Class IIb medical device. ISO 13485:2016 quality system certification for the manufacturer. Oxygen output compliant with EN ISO 7396-1 pipeline standards. Pharmacopoeia (Oxygen 93) purity grade.
ULTRAOX is certified CE 1639 under MDR Class IIb.
PSA generation produces oxygen on-site continuously from ambient air, eliminating delivery dependencies. LOX requires regular tanker deliveries from specialist suppliers and cold storage infrastructure.
PSA is typically more cost-effective above 10 to 15 Nm³/hour continuous demand and provides supply chain independence. LOX may suit very large urban hospitals with reliable supplier access and high daily oxygen consumption.
Yes. The containerised ULTRAOX CO system is specifically designed for deployment in extreme environments, including:
Deserts, tropical climates, high-altitude locations, coastal humidity, and sites with no existing technical infrastructure. ULTRAOX systems are operating in environments ranging from the Sahara to coastal Cabo Verde to high-altitude Andean clinics.
The capital investment in a PSA system is typically recovered within 12 to 36 months, depending on the facility's oxygen consumption and the local cost of cylinder supply.
Over a 10-year operational lifespan, savings often exceed 70 percent of the equivalent cylinder supply cost.
ULTRAOX consistently delivers oxygen at up to 95% purity, exceeding the minimum 93% purity required by both European Pharmacopoeia and United States Pharmacopeia for medical oxygen produced by PSA methods (Oxygen 93 grade).
ULTRAOX is engineered and manufactured in Lisbon, Portugal by Ultra Controlo since 1981.
The systems are deployed in hospitals, ministries of health, UN agencies, and NGO programmes across more than 80 countries, including Cabo Verde, Mali, Angola, Yemen, Peru, Bangladesh, and many others across Africa, the Middle East, Latin America, and Southeast Asia.
Ultra Controlo provides free project assessments, system sizing consultations, and technical support throughout the procurement and installation process. Our engineering team in Lisbon is available to discuss your facility, your timeline, and your compliance requirements.